MASIMO CORP (MASI) 144.85 +1.83 (+1.28%)
144.85 +1.83 (+1.28%)
US5747951003 - Common Stock - After market: 144.85 0 (0%)
Fundamental Rating
Overall MASI gets a fundamental rating of 5 out of 10. We evaluated MASI against 220 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of MASI get a neutral evaluation. Nothing too spectacular is happening here. MASI is valued quite expensive, but it does show an excellent growth.
Profitability
Profitability Rating
MASI has a Return On Assets of 5.59%. This is amongst the best returns in the industry. The industry average is -18.33%. MASI outperforms 85% of its industry peers.
MASI's Return On Equity of 13.64% is amongst the best of the industry. MASI does better than the industry average Return On Equity of 10.59%.
MASI has a Profit Margin of 9.78%. This is amongst the best returns in the industry. The industry average is -28.22%. MASI outperforms 82% of its industry peers.
The Piotroski-F score of MASI is 3.00. This is a low score and indicates issues in the health and profitability of MASI.
VS Industry
ROA (5.59%) VS Industry: 85% outperformed.
-771.54
117.69
ROE (13.64%) VS Industry: 63% outperformed.
0.69
140.68
Profit Margin (9.78%) VS Industry: 82% outperformed.
-142,068.42
1,450.19
Valuation
Valuation Rating
When comparing the current price to the book value of MASI, we can conclude it is valued correctly. It is trading at 6.08 times its book value.
The Price/Earnings Ratio is 32.26, which means the current valuation is very expensive for MASI.
Compared to an average industry Price/Earning Ratio of 23.49, MASI is valued slightly more expensive.
With a Forward Price/Earnings Ratio of 27.92, MASI is valued very expensively.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
Compared to an average industry price book ratio of 2.50, MASI is valued more expensive than its industry peers.
Compared to an average industry Enterprise Value to EBITDA ratio of 13.58, MASI is valued more expensive than its industry peers. 85% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (32.26) VS Industry: 30% outperformed.
1,781.27
0.05
Price/Book (6.08) VS Industry: 23% outperformed.
1,010.07
0.10
Enterprise Value/ EBITDA (28.2) VS Industry: 15% outperformed.
4,691.61
0.04
Growth
Growth Rating
MASI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.41%, which is quite good.
MASI shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 12.44% yearly.
Based on estimates for the next 5 years, MASI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.32% on average per year.
The Revenue has grown by 44.74% in the past year. This is a very strong growth!
Measured over the past 5 years, MASI shows a quite strong growth in Revenue. The Revenue has been growing by 11.69% on average per year.
Based on estimates for the next 5 years, MASI will show a quite strong growth in Revenue. The Revenue will grow by 18.74% on average per year.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 12.44% | 8.89% | 19.41% | 13.7% | 14.03% | 14.59% | 14.32% |
| Revenue | 11.69% | 13.02% | 44.74% | 64.09% | 40.15% | 29.17% | 18.74% |
Health
Health Rating
A Current Ratio of 2.12 indicates that MASI has no problem at all paying its short term obligations.
MASI has an Altman-Z score of 4.38. This indicates that MASI is financially healthy and little risk of bankruptcy at the moment.
When comparing the Altman-Z score to an average industry score of 1.87, MASI is in better financial health than the average industry peer.
MASI has a Quick Ratio of 1.28. This is a normal value and indicates that MASI is financially healthy and should not expect problems in meeting its short term obligations.
When comparing the Current Ratio of MASI to the average industry Current Ratio of 3.60, MASI is less able to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of MASI to the average industry Current Ratio of 2.91, MASI is less able to pay its short term obligations than its industry peers. 81% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.09, MASI is requires more financing than its industry peers. 85% of its industry peers have a better Debt to Equity Ratio.
MASI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of MASI.
VS Industry
Debt/Equity (0.76) VS Industry: 15% outperformed.
336.87
0.00
Quick Ratio (1.28) VS Industry: 19% outperformed.
0.06
31.22
Current Ratio (2.12) VS Industry: 24% outperformed.
0.13
31.22
Altman-Z (4.38) VS Industry: 71% outperformed.
-105.06
70.14
Dividend
Dividend Rating
No dividends for MASI!.
MASIMO CORP144.85
NASDAQ:MASI (11/25/2022, 7:13:39 PM)+1.83 (+1.28%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Equipment & Supplies | ||
| Earnings (Last) | 11-08 2022-11-08/amc | Earnings (Next) | 02-13 2023-02-13 |
| Ins Owners | 1.03% | Inst Owners | 88.26% |
| Market Cap | 7.61B | Analysts | 81.43 |
| PE | 32.26 | Fwd PE | 27.92 |
| PEG (NY) | 2.36 | PEG (5Y) | 2.59 |
| P/S | 4.36 | P/B | 6.08 |
| EV/EBITDA | 28.2 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | 0% | Ex-Date | N/A |
| EPS 1Y | 19.41% | EPS 3Y | 8.89% |
| EPS 5Y | 12.44% | EPS growth Q2Q | 6.38% |
| EPS Next Y | 13.7% | EPS Next 2Y | 14.03% |
| EPS Next 3Y | 14.59% | EPS Next 5Y | 14.32% |
| Revenue growth 1Y | 44.74% | Revenue growth 3Y | 13.02% |
| Revenue growth 5Y | 11.69% | Revenue growth Q2Q | 78.68% |
| Revenue Next Year | 64.09% | Revenue Next 2Y | 40.15% |
| Revenue Next 3Y | 29.17% | Revenue Next 5Y | 18.74% |
| Current Ratio | 2.12 | Quick Ratio | 1.28 |
| Altman-Z | 4.38 | F-Score | 3 |
| Debt/Equity | 0.76 | WACC | 9.2% |
| ROIC/WACC | 2 | ||
| ROA | 5.59% | ROE | 13.64% |
| ROICexgc | 18.41% | ROIC | 8.16% |
| PM | 9.78% | OM | 13.21% |
| Asset Turnover | 0.57 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA